Sinil Pharmaceutical Co. Ltd - Asset Resilience Ratio

Latest as of September 2025: 17.46%

Sinil Pharmaceutical Co. Ltd (012790) has an Asset Resilience Ratio of 17.46% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See working capital position of Sinil Pharmaceutical Co. Ltd to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

₩29.67 Billion

≈ $20.11 Million USD Cash + Short-term Investments

Total Assets

₩169.94 Billion

≈ $115.16 Million USD All company assets

Resilience Assessment

Good

Financial Resilience Level

Asset Resilience Ratio Trend (2014–2024)

This chart shows how Sinil Pharmaceutical Co. Ltd's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Sinil Pharmaceutical Co. Ltd assets under control.

Liquid Assets Composition Over Time

This chart breaks down Sinil Pharmaceutical Co. Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore Sinil Pharmaceutical Co. Ltd (012790) investment intensity to see how much of total assets are deployed in long-term investments.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	₩0.00	0%
Short-term Investments	₩29.67 Billion	17.46%
Total Liquid Assets	₩29.67 Billion	17.46%

Asset Resilience Insights

Good Liquidity Position: Sinil Pharmaceutical Co. Ltd maintains a healthy 17.46% of assets in liquid form.
This level provides good financial flexibility while maintaining productive asset deployment.
The company has significant short-term investments, indicating active treasury management.

Sinil Pharmaceutical Co. Ltd Industry Peers by Asset Resilience Ratio

Compare Sinil Pharmaceutical Co. Ltd's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Kamada TA:KMDA	Drug Manufacturers - Specialty & Generic	0.00%
Takeda Pharmaceutical Co Ltd ADR NYSE:TAK	Drug Manufacturers - Specialty & Generic	4.94%
Viatris Inc NASDAQ:VTRS	Drug Manufacturers - Specialty & Generic	1.48%
Takeda Pharmaceutical Company Limited F:TKDA	Drug Manufacturers - Specialty & Generic	0.69%
Shijiazhuang Yiling Pharmaceutical Co Ltd SHE:002603	Drug Manufacturers - Specialty & Generic	11.60%
Chengdu Kanghong Pharmaceuticals Group Co Ltd SHE:002773	Drug Manufacturers - Specialty & Generic	4.31%
Yipinhong Pharmaceutical Co Ltd Class A SHE:300723	Drug Manufacturers - Specialty & Generic	1.01%
Avadel Pharmaceuticals PLC NASDAQ:AVDL	Drug Manufacturers - Specialty & Generic	5.90%

Annual Asset Resilience Ratio for Sinil Pharmaceutical Co. Ltd (2014–2024)

The table below shows the annual Asset Resilience Ratio data for Sinil Pharmaceutical Co. Ltd.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2024-12-31	20.31%	₩33.69 Billion ≈ $22.83 Million	₩165.86 Billion ≈ $112.40 Million	+4.96pp
2023-12-31	15.35%	₩23.41 Billion ≈ $15.86 Million	₩152.46 Billion ≈ $103.32 Million	-0.97pp
2022-12-31	16.32%	₩23.31 Billion ≈ $15.80 Million	₩142.83 Billion ≈ $96.79 Million	+0.16pp
2021-12-31	16.16%	₩20.84 Billion ≈ $14.12 Million	₩128.97 Billion ≈ $87.40 Million	+4.48pp
2020-12-31	11.68%	₩14.57 Billion ≈ $9.88 Million	₩124.81 Billion ≈ $84.58 Million	+0.17pp
2019-12-31	11.50%	₩13.56 Billion ≈ $9.19 Million	₩117.84 Billion ≈ $79.86 Million	-1.32pp
2018-12-31	12.83%	₩13.65 Billion ≈ $9.25 Million	₩106.40 Billion ≈ $72.11 Million	-0.10pp
2017-12-31	12.93%	₩13.25 Billion ≈ $8.98 Million	₩102.52 Billion ≈ $69.48 Million	-1.86pp
2016-12-31	14.79%	₩14.50 Billion ≈ $9.83 Million	₩98.05 Billion ≈ $66.45 Million	-2.98pp
2015-12-31	17.77%	₩15.51 Billion ≈ $10.51 Million	₩87.26 Billion ≈ $59.14 Million	-0.66pp
2014-12-31	18.43%	₩14.73 Billion ≈ $9.98 Million	₩79.91 Billion ≈ $54.15 Million	--

pp = percentage points

About Sinil Pharmaceutical Co. Ltd

KQ:012790 Korea Drug Manufacturers - Specialty & Generic

Market Cap

$47.47 Million

₩70.05 Billion KRW

Market Cap Rank

#22181 Global

#1383 in Korea

Share Price

₩6060.00

Change (1 day)

+1.00%

52-Week Range

₩4900.00 - ₩6480.00

All Time High

₩50717.45